找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Antitumor Potential and other Emerging Medicinal Properties of Natural Compounds; Evandro Fei Fang,Tzi Bun Ng Book 2013 Springer Science+B

[復(fù)制鏈接]
樓主: 解毒藥
31#
發(fā)表于 2025-3-26 22:39:42 | 只看該作者
32#
發(fā)表于 2025-3-27 02:15:42 | 只看該作者
Antitumor Potential and other Emerging Medicinal Properties of Natural Compounds
33#
發(fā)表于 2025-3-27 07:50:20 | 只看該作者
Antitumor Potential and other Emerging Medicinal Properties of Natural Compounds978-94-007-6214-5
34#
發(fā)表于 2025-3-27 11:53:45 | 只看該作者
35#
發(fā)表于 2025-3-27 14:27:15 | 只看該作者
36#
發(fā)表于 2025-3-27 20:29:17 | 只看該作者
37#
發(fā)表于 2025-3-27 23:25:26 | 只看該作者
Middleware und Realisierungsalternativene been used in the therapy of cancer and other incurable diseases with potential promising results and failures. In the last decade, many research efforts have been dedicated to the development of more efficient and less immunogenic chimeric fusions. In this chapter we will mainly focus on plant RIP
38#
發(fā)表于 2025-3-28 04:39:59 | 只看該作者
Yao Hui Lei,Gang Mai,Esma A?meur(with measurements of prostate specific antigen levels and prostate volume, etc.), treatment of ulcerative colitis, gingivitis, or esophagitis (and/or alleviation of adverse side effects of lung cancer treatment), as described elsewhere [.]. There are numerous publications on the results from these
39#
發(fā)表于 2025-3-28 06:19:36 | 只看該作者
Standards in Electronic Commerce (1)splay well-defined, rigid structures and, unlike most proteins, are also resistant to denaturizing agents. Modifications introduced into the molecules of these low-molecular-mass inhibitors are well tolerated, retaining their tertiary structure and inhibitory activity. They are able to cross cell me
40#
發(fā)表于 2025-3-28 11:01:05 | 只看該作者
enowned experts exploring the different uses of medicinal compounds in human therapeutics. Here we provide a comprehensive outlook on both qualitative and quantitative studies focusing on medicinal plants and animals, and establishing a link between laboratory research discovery and clinical applications.978-94-017-8529-7978-94-007-6214-5
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-13 10:15
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
泗阳县| 闽清县| 武山县| 云霄县| 宁国市| 肇东市| 商洛市| 县级市| 乐至县| 商城县| 敦煌市| 汶上县| 晋宁县| 常熟市| 壤塘县| 唐海县| 仪陇县| 满城县| 县级市| 峨眉山市| 集安市| 明星| 怀来县| 商丘市| 象州县| 佛坪县| 维西| 嘉义县| 兴化市| 昌黎县| 巴里| 巩义市| 合川市| 广河县| 右玉县| 正蓝旗| 绥化市| 双城市| 抚远县| 鄂尔多斯市| 泽普县|